on Evotec AG (NASDAQ:EVTCY)
Evotec SE to Release First Half-Year Results 2025
Hamburg-based Evotec SE is set to release its half-year interim report for the first six months of 2025 on 13 August. The company will discuss its performance during a conference call held in English on the same day. Stakeholders can join via an audio webcast, with registration required to access presentation slides and detailed information.
Evotec, listed on the Frankfurt Stock Exchange and NASDAQ, is a prominent player in the life sciences sector. The company integrates advanced technologies with AI-driven innovation to expedite drug discovery and development.
Evotec is known for its comprehensive R&D capabilities, strategic partnerships, and a robust portfolio of over 100 R&D assets targeting critical therapeutic areas like oncology and neurology.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Evotec AG news